Your browser doesn't support javascript.
loading
Serum Folate deficiency in HCV related Hepatocellular Carcinoma.
Malaguarnera, Giulia; Catania, Vito Emanuele; Bertino, Gaetano; Drago, Filippo; Madeddu, Roberto; Bonfiglio, Claudia; Malaguarnera, Michele.
Afiliación
  • Malaguarnera G; Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy.
  • Catania VE; Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
  • Bertino G; Department of Experimental and Clinical Medicine, University of Catania, Policlinico "G. Rodolico", Via S. Sofia n.78, 95123, Catania, Italy. gaetanobertinounict@gmail.com.
  • Drago F; Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy.
  • Madeddu R; Department of Biomedical Sciences, University of Sassari, Catania, Italy.
  • Bonfiglio C; Medical Centre INPS Catania-Italy, Catania, Italy.
  • Malaguarnera M; Department of Biomedical and Biotechnological Science, University of Catania, Catania, Italy.
Sci Rep ; 12(1): 5025, 2022 03 23.
Article en En | MEDLINE | ID: mdl-35322130
Nutritional and environmental factors had been reporting in the progression of hepatocellular carcinoma (HCC). In this study, we focused our intervention in the correlation between the folate status and the progression of HCC in patients with chronic virus C (HCV) infection. Nine-eight patients, HCV positive with HCC and one hundred of patients with HCV positive liver cirrhosis (LC) and one hundred patients with HCV positive chronic hepatitis (CHC) and one hundred control subjects were enrolled. The viremia for hepatitis C patients (HCV) was determined by HCV RNA with polymerase chain reaction. HCV was confirmed by HCV RNA or a positive anti-HCV test with chronic liver disease. The comparison of folate serum levels in HCC patients vs Liver Cirrhosis (LC) patients showed a significant decrease of 1.16 ng/ml P = 0.0006 (95% CI-1.925 to - 0.395), in HCC patients versus CHC a decrease of 1.40 ng/ml P < 0.0001 (95% CI-2.16 to - 0.63), in HCC vs controls a decrease of 3.80 ng/ml P < 0.0001 (95% CI-4.56 to - 3.03). The comparison of homocysteine Hcy serum levels showed a significant increase in HCC vs LC of 4 nmol/L (P < 0.0001, 95% CI 2.77 to 5.22) versus CHC of 9 nmol/L (P < 0.0001, 95% CI 7.78 to 10.22) and vs Controls 9.30 nmol/L (P < 0.0001, 95% CI 8.07 to 10.52). With progression of HCV infection from chronic hepatitis to cirrhosis, then to HCC development, serum folate levels are progressively decreasing together with a progressive increase in serum homocysteine levels reflecting its role in disease progress and carcinogenesis.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis C / Carcinoma Hepatocelular / Hepatitis C Crónica / Neoplasias Hepáticas Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hepatitis C / Carcinoma Hepatocelular / Hepatitis C Crónica / Neoplasias Hepáticas Tipo de estudio: Etiology_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido